Dr. Fares Saeed Al Ma

Assistant professor

College of Medical Applied Sciences 
Clinical Laboratory Sciences 
Histopathology
 

0552541012
fsalmansour@nu.edu.sa

Qualifications

Doctor of Philosophy in Mechanism of Cancer and Ageing, University of Leicester, United Kingdom, (2019-2023).
Master of Laboratory Medicine, Royal Melbourne Institute of Technology university, Australia, (2016-2017).
English for Academic Purposes at Advanced Level, RMIT English Worldwide – Melbourne Center, Australia,
(2014-2015).
Bachelor of Medical Laboratory Sciences Najran University, Saudi Arabia, (2009-2013)

Experiences

Novel Approaches to Eliminate Senescent Cells for The Amelioration of Age-related Diseases

Specialties and Skills

المهام الوظيفية

Training Courses

Young International Senescence Association, UK, 2023

Innovate Colloquium on Biotechnology & Industrial Revolution, Australia, 2017

Scientific Research

Al-Mansour F, Alraddadi A, He B, Saleh A, Poblocka M, Alzahrani W, Cowley S, Macip S. Characterization of the HDAC/PI3K inhibitor CUDC-907 as a novel senolytic. Aging (Albany NY). 2023 Apr 4;15(7):2373.

Almasoudi HH, Nahari MH, Alhazmi AY, Almasabi SH, Al-Mansour FS, Hakami MA. Delineating Pixantrone Maleate’s adroit activity against cervical cancer proteins through multitargeted docking-based MM\GBSA, QM-DFT and MD simulation. Plos one. 2023 Dec 15;18(12):e0295714.

Almasoudi, H.H., Mashraqi, M.M., Alshamrani, S.A., Alharthi, A.A., Alsalmi, O., Nahari, M.H., Al-Mansour, F.S.H. and Alhazmi, A.Y.M., 2024. Structure-Based In Silico Approaches Reveal IRESSA as a Multitargeted Breast Cancer Regulatory, Signalling, and Receptor Protein Inhibitor. Pharmaceuticals, 17(2), p.208.

Al-Mansour FS, Almasoudi HH, Albarrati A. Mapping molecular landscapes in triple-negative breast cancer: insights from spatial transcriptomics. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025 Mar 22:1-9.

Almasabi SH, Almasoudi HH, Albargy H, Alabbas MM, Al-Mansour FS. Alternative use of droxidopa for treating cervical cancer: inhibiting transferase, cell cycle signalling, and transport proteins via multitarget docking, DFT, MD simulations, and binding free energy studies. Medical Oncology. 2025 May;42(5):1-23.

Alraddadi A, Smalley JP, Alzahrani W, Saleh A, Al?Mansour F, He B, Cao TH, Jayne S, Dyer M, Hodgkinson JT, Jones DJ. Targeted Degradation of Class 1 HDACs With PROTACs is Highly Effective at Inducing DLBCL Cell Death. EJHaem. 2025 Aug;6(4):e70127.
 

 

Courses

Histopathology-2

office Hours

الوصف

  8-9 9-10 10-11 11-12 12-1 1-2
الأحد
Sunday		     Histopathology-2
office C-185		      
الاثنين
Monday		     Histopathology-2
office C-185		      
الثلاثاء
Tuesday		     Histopathology-2
office C-185		      
الأربعاء
Wednesday		     Histopathology-2
office C-185		      
الخميس
Thursday		     Histopathology-2
office C-185